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Pulmonary emphysema is a major cause of mortality and morbidity in chronic obstructive pulmonary disease (COPD). Cigarette smoking is a
major risk factor in the development of pulmonary emphysema. In this study, we investigated the acute effect of cigarette smoke in vitro on the
production of tumour necrosis factor-α (TNF-α) using differentiated U937 cells, a macrophage model system. We found that stimulation of the
macrophages with cigarette smoke media (CSM) leads to a rapid activation of extracellular-regulated kinases 1 and 2 (erk1/2), p90RSK and a
transient decrease in phosphorylation of PKB/akt. The CSM also caused the subsequent induction of TNF-α release. Our studies revealed that
U0126, an inhibitor of the erk1/2 pathway, markedly suppressed CSM-induced TNF-α release. Consistent with this finding, U0126 blocked CSM-
stimulated erk1/2 phosphorylation, as well as phosphorylation of the downstream kinase, p90RSK. On the other hand, the PI3-K inhibitor,
LY294002, and epidermal growth factor receptor (EGFR)-specific inhibitor, AG1478, did not suppress the release of TNF-α. Thus, CSM
induction of TNF-α production by differentiated macrophages is regulated primarily via the erk1/2 pathway.
© 2006 Elsevier B.V. All rights reserved.Keywords: Macrophage; In vitro cigarette smoke exposure; Tumour necrosis factor-α; erk1/21. Introduction
Currently, chronic obstructive pulmonary disease (COPD) is
the fourth leading cause of death in the United States, and
worldwide incidences are rising due to a widespread increase in
tobacco consumption, particularly among women and adoles-
cents [1]. COPD commonly refers to chronic bronchitis and
emphysema. Pulmonary emphysema is defined as permanent
airspace enlargement beyond the terminal bronchioles, with the
destruction of alveolar walls and without obvious fibrosis [2].
Cigarette smoking is by far the major risk factor for
development of pulmonary emphysema; however, other factors,
such as pollution, α1-antitrypsin deficiency and occupational
factors, also play a role.Abbreviations: TNF-α, tumour necrosis factor-α; erk1/2, extracellular-
regulated kinases 1 and 2; ELISA, enzyme linked immunosorbent assay; CSM,
cigarette smoke media
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doi:10.1016/j.bbadis.2006.04.004A commonly accepted theory for the pathogenesis of
cigarette smoke-induced emphysema is the protease–anti-
protease hypothesis. Cigarette smoke induces an inflammatory
response within the lung; these recruited inflammatory cells are
composed of a heterogeneous population of neutrophils,
macrophages and T lymphocytes (predominantly CD8+ cells).
Macrophages and neutrophils are the two major inflammatory
cells within the lung that release various proteolytic enzymes in
excess of their natural inhibitors leading to tissue destruction
and airway enlargement [3–5]. However, a key factor in the
pathogenesis of emphysema is the inflammatory reaction within
the lung; hence, identifying specific cytokines or mediators that
orchestrate inflammatory cell recruitment to the lung may lead
to a better understanding of the pathogenesis of the disease.
Macrophages orchestrate the primary response to external
stimuli when defending the body; they are the major defence
cells in the lower airspace of the lung in healthy nonsmokers
and appear to have an essential role in the pathogenesis of
COPD by accounting for most known features of the disease
[6]. Bronchoalveolar lavage (BAL) fluid from smokers
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number of inflammatory cells in the lung, of which 85–90%
are alveolar macrophages. Macrophages are predominant
cells in the respiratory bronchioles of smokers; studies have
shown a correlation between alveolar macrophage numbers
and the extent of lung destruction in emphysema [7,8].
Activated macrophages release various inflammatory pro-
teins, such as cytokines, chemokines and proteolytic
enzymes. TNF-α is one of the acute pro-inflammatory
cytokines secreted by macrophages and plays a central role
in inducing the recruitment of inflammatory cells to the lung
in a variety of pulmonary diseases [9].
TNF-α plays an important role in defence of the body against
foreign pathogens such as virus, bacteria and fungi. In humans,
TNF-α is synthesized as a 31-kDa precursor molecule;
however, prior to secretion, the N-terminal sequence is removed
leading to the release of a 17-kDa polypeptide [10]. TNF-α can
bind to two different cell surface receptors p55 (TNFR1) or p75
(TNFR2). The main receptor in the TNF-α response is the p55
receptor which induces a variety of biological effects, whereas
the p75 receptor is the prototype member of the death receptor
family and is responsible for cytotoxic effects [11].
A variety of cells produce TNF-α, including neutrophils, T
cells, macrophages, monocytes, epithelial cells, fibroblasts and
smooth muscle cells [12,13]; however, the principle source of
TNF-α in the lung is the alveolar macrophages. TNF-α
production within the lung can play a central role in inducing
the expression of adhesion molecules, including ICAM-1,
VCAM-1 and E-selectin. It can also stimulate the expression of
various cytokines such as interleukin(IL)-1, IL-6, IL-8, platelet-
derived growth factor (PDGF), granulocyte macrophage colony
stimulating factor (GM-CSF), monocyte chemoattractant pro-
tein-1 (MCP-1) and macrophage inflammatory protein 2 (MIP-
2) [14–17]. This increase in the levels of chemokines, cytokines
and adhesion molecules results in the activation and recruitment
of neutrophils and macrophages to the lung and ultimately leads
to tissue destruction.
There have been relatively few previous studies investigating
effects of cigarette smoke products on cell signaling pathways
in macrophages [18–20]. In this study, we investigated the
effect of CSM on TNF-α release by macrophages and the
relative importance of several signaling pathways in mediating
TNF-α production due to CSM exposure. Use of CSM remains
a good practical model to study changes in cellular responses
induced by cigarette smoke. While some studies have focused
on the effects of individual cigarette smoke components, our
interest was in testing the effect of whole cigarette smoke, and
therefore, CSM was used to mimic the in vivo soluble cigarette
smoke components that are present during cigarette smoking.
2. Materials and methods
2.1. Materials
The human monocytic cells, U937 cell line was obtained from the American
Type Culture Collection (Manassas, USA). RPMI-1640, L-glutamine, strepto-
mycin–penicillin and fetal bovine serum were purchased from Stem Cell
Technologies (Vancouver, BC, Canada). The PathScan Multiplex westerncocktail I consists of phospho-p90RSK (Ser-380), phospho-PKB (Ser-473),
phospho-erk1/2 (Thr-202/Tyr-204), phospho-S6 ribosomal protein (Ser 235/
236), elF4E antibody; the cocktail and MEK 1/2 inhibitor U0126 were
purchased from Cell Signaling Technology (Beverly, MA). Anti-rabbit IgG
horseradish peroxidase-conjugated secondary antibody, EGFR-specific inhibitor
AG1478 and PI3-K inhibitor LY294002 were purchased from Calbiochem (La
Jolla, CA). The high molecular weight protein standard for Western blotting was
purchased from BioRad (Hercules, CA). ECL (enhanced chemiluminescence)
reagent was purchased from Amersham (Buckinghamshire, UK), and the human
TNF-α Elisa kit was purchased from R&D Systems (Minneapolis, MN).
2.2. Cell culture
U937 cells were cultured in 75-cm2 tissue culture flasks with RPMI medium
supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine,
10 mMHEPES and streptomycin–penicillin in a humidified atmosphere of 95%
air and 5% C02 at 37 °C. Cells in the culture flasks were maintained at a density
of between 1×105 cells/ml and 2×106 cells/ml. Cells were harvested, then
plated in 6-well tissue culture plates (2×106 cells/2 ml/well) and stimulated with
20 ng/ml of phorbol myristate acetate (PMA, Sigma) for 48 h resulting in
adherent differentiated macrophages. Adherent cells were washed twice with
RPMI-1640, followed by the addition of fresh RPMI-1640 medium in the
absence of PMA for an additional 24 h. Differentiated U937 cells represent a
viable model for macrophages and therefore were used instead of primary
human macrophages due to their availability and reproducibility over primary
human cells, which are more difficult to obtain, and in which we have found
signaling responses to be too variable to do the type of study we have described
here.
On the day of smoke exposure, cells were washed twice with RPMI followed
by the addition of fresh RPMI and incubated for 2 h prior to smoke exposure.
For the experiments with MEK1/2 inhibitor U0126, EGFR-specific inhibitor
AG1478 and PI3-K inhibitor LY294002, cells were pre-incubated with 10 μMof
U0126, 10 nM of AG1478 and 6 μM of LY294002 for 1 h prior to smoke
exposure and compared to control cultures that were not treated with inhibitors.
2.3. Exposure of cultures to cigarette smoke medium
Cigarette smoke generated from two medium tar commercial filtered
cigarettes (Rothmans Blue) was bubbled through 25 ml of RPMI-1640. Eight
puffs of 30 ml of smoke from each cigarette were withdrawn using a 60-ml
syringe over 10 s and then bubbled through 25 ml of RPMI in 30 s. We chose
8 puffs of 30 ml of smoke from each cigarette by considering that a smoker will
inhale about 30 ml of smoke per puff and that a cigarette will be consumed by a
smoker with 8 puffs. The media pH was adjusted to 7.2–7.4 and diluted to
achieve an optical density reading of 1.0 at 320 nm [35]. This was defined as
100% CSM. CSMwas prepared in a non-sterile environment and thus to remove
particles and to minimize risk of bacterial contamination, the CSM was filtered
through a 0.2-μm pore filter. Prior to each smoke exposure, CSM was freshly
prepared within an hour and diluted with medium to achieve the desired %
concentration of CSM. Cells were treated with 0 (Control; air bubbled medium),
2.5, 5, 10, 15 and 20% of CSM, and cell viabilities following treatment were
always greater than 95% as measured by trypan blue exclusion. The media were
collected at 18, 24 and 48 h, centrifuged at 1000 rpm for 10 min and then stored
at −70 °C.
2.4. TNF-α enzyme linked immunosorbent assay (ELISA)
TNF-α levels in the cell culture supernatant of control and CSM-exposed
differentiated U937 cells were quantified by ELISA following the manufacture's
instructions (R&D Systems). Briefly, 96-well plates (NUNC, MaxiSorpTM
Surface) were coated with monoclonal anti-human TNF-α antibody (4 μg/ml) at
4 °C overnight. The wells were then washed 3 times with PBS–0.05% Tween 20
and then blocked with 1%BSA in PBS for 1 h. The plate was washed again,
followed by the addition of samples and standards in duplicate, and incubated
for 2 h at room temperature. The washing step was repeated and biotinylated
goat anti-human TNF-α (75 ng/ml) was added and incubated for 2 h at room
temperature. The wells were washed again, and streptavidin–HRP was added
Fig. 1. Dose- and time-dependent effect of CSM on TNF-α release by
macrophages. [A] TNF-α release by macrophages treated with 10% CSM for 3,
6, 9, 18, 24 and 48 h. CSM induced a time-dependent release in TNF-α. [B]
Macrophages were treated with the indicated percentages of CSM for 18, 24 and
48 h. CSM induced a dose-dependent release of TNF-α. Each bar represents the
mean value±S.D. from 7 independent experiments. CSM caused a significant
increase in TNF-α (P<0.05) at concentrations of 5, 10, 15 and 20%. TNF-α
release in media was measured by ELISA.
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5′-tetramethylbenzidine) was added as a substrate and incubated for 1 h at room
temperature, the reaction was stopped by the addition of H2SO4 (2N) and read at
450 nm.
2.5. Immunoblot analysis
Immunoblot analyses for phospho-proteins were performed on control and
CSM-exposed differentiated U937 cells. The cells were serum-deprived for 2
h prior to stimulation with CSM. Control and treated cells (2×106 cells) were
washed 3 times with ice cold phosphate-buffered saline (PBS) followed by the
addition of 125 μl of ice-cold lysis buffer (50 mM Tris buffer pH 7.4, 1% Triton
X-100, 10% glycerol, 100 mM NaCl, 2.5 mM EDTA, 10 mM NaF, 0.2 mM Na
orthovanadate, 1 mMNa molybdate, 40 μg/ml PMSF, 1 μMpepstatin, 0.5 μg/ml
leupeptin, 10 μg/ml soybean trypsin inhibitor). Lysates were collected and
centrifuged at 13,000 rpm for 10 min at 4 °C, the supernatant containing protein
was collected and the precipitates discarded. The protein concentrations of
extracts were quantified by the Pierce protein assay. 5× sample buffer was added
to each sample and heated at 90 °C for 4 min. High molecular weight standard
(BioRad) and samples of equal protein quantities were loaded and separated on a
12% SDS-polyacrylamide gel.
The proteins were then transferred onto nitrocellulose paper by semi-dry
blotting. After transfer, blots were stained with Ponceau Red for 1 min to
confirm equal protein transfer to each blot. The membrane was then blocked
with 5% skim milk in Tris-buffered saline containing 0.05% Tween 20 (TBST)
for 1.5 h followed by incubation with the primary antibody overnight in 5%
BSA/TBST at 4 °C. Membranes were then washed twice in TBST for 15 min at
room temperature, then incubated with horseradish peroxidase-conjugated
secondary antibody (1:2000 dilution) for 1 h at room temperature. The
immunoblots were visualized with ECL reagent. Densitometry analysis of
phospho-erk1/2 was performed using a Fluorchem TM 800 (Alpha Innotech
Corporation, San Leandro, CA) high sensitivity digital camera system. Pixel
density for the appropriate bands was captured, and the camera system software
was used for the analysis of data.
2.6. Statistics
The data for TNF-α release are expressed as mean±standard deviation.
Results were analyzed by the Student's t test at a confidence level of P≤0.05.
3. Results
3.1. Cigarette smoke media stimulates TNF-α release by
macrophages
To evaluate the time effect of CSM on TNF-α release,
macrophages were treated with 10% CSM for 3, 6, 9, 18, 24 and
48 h. Controls were macrophages treated with air-exposed media.
TNF-α released in the media of the macrophages was assayed by
ELISA. We observed that the effect of CSM on TNF-α release
was time dependent. CSM induced TNF-α release as early as 3 h
and peaked at 24 and 48 h (Fig. 1A). We then tested the effect of
CSM on TNF-α release in a dose response experiment.
Macrophages were treated with 0, 2.5, 5, 10, 15 and 20% CSM
for 18, 24 and 48 h. Results indicate that CSM induces
statistically significant release of TNF-α in a dose-dependent
manner (Fig. 1B) following exposures to more than 2.5% CSM.
3.2. Activation of erk1/2 MAP kinases and deactivation of PKB
by CSM
We investigated the effect of CSM on the activation of
p90RSK, erk1/2, PKB and p70 S6 kinase in macrophages usinga cocktail of specific antibodies. This was accomplished by
immunoblotting with antibodies that detect only the phosphor-
ylated and activated forms of the p90RSK, erk1/2 and PKB
kinases, as well as an antibody detecting phosphorylated S6
ribosomal protein, a target of p70 S6 kinase. Macrophages
treated with 5 and 10% of CSM showed the most significant
change in the activity of erk1/2. There was a greater than
twofold increase in the activity of erk1/2, with a corresponding
consistent decrease in the activity of PKB after 15 min of CSM
exposure; however, at 30 min of exposure, the activity of PKB
was back to control levels (Fig. 2). The phosphorylation of
p90RSK and S6 ribosomal protein was also assayed with
antibodies to the phosphorylated forms of these proteins.
Activation of the p90RSK kinase is at least partially dependent
upon erk1/2 activation, while phosphorylation of the S6
ribosomal protein is a reliable measure of the activation of
p70S6K. Exposure to CSM was found to activate p90RSK,
while there was no consistent change in the activity of p70S6K,
based on the level of phosphorylation of the S6 protein (Fig. 2).
3.3. Effect of MEK1/2 inhibitor U0126 on TNF-α release by
CSM
To elucidate the intracellular signaling mechanism by which
CSM induces TNF-α release, we investigated whether the
activation of the erk1/2 pathway was necessary for CSM
Fig. 2. CSM induces activation of erk1/2 and p90RSK, and decreased activation
of PKB. [A] Phosphorylation of erk1/2, PKB, p90RSK and S6 ribosomal protein
was analyzed by Western blot. 2×106 macrophages/well were treated with 5 and
10% CSM for 15 and 30 min. Whole cell lysates were analyzed.
Immunoblotting for elF4E was included as a control for protein loading. [B]
Quantitative densitometry result of phospho-ERK1/2 in (A) was normalized
against elF4E protein content.
Fig. 3. erk1/2 is a mediator in CSM-induced TNF-α release. [A] TNF-α release
without (red bar) or with (blue bar) pretreatment with MEK 1/2 inhibitor U0126
(10 μM). The inhibitor blocked release of TNF-α following exposure to 2.5, 5,
10, 15 and 20% CSM for 24 h, indicating that release is dependent on ERK1/2
activation. Each bar represents the mean value±S.D. from 3 independent
experiments. TNF-α released in media was assayed by ELISA. (B) Western blot
analysis from macrophages treated with U0126 for 1 h prior to treatment with
2.5, 5 and 10% CSM for 15 min. Treatment with U0126 did not affect the
viability of U937 cells.
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Cells incubated with and without pretreatment with MEK1/2
inhibitor U0126 (10 μM) (Cell Signaling Technology, Beverly,
MA) for 1 h were exposed to 2.5, 5, 10, 15 and 20% of CSM for
24 h. The inhibitor U0126 completely blocked TNF-α release,
indicating that TNF-α release in response to CSM exposure is
dependent on the activation of erk1/2 (Fig. 3). In contrast, PI3-K
inhibitor LY294002 and EGFR-specific inhibitor AG1478 had
no effect on CSM-induced TNF-α release by macrophages (Fig.
4). U0126, AG1478 and LY294002 did not affect the viability
of the macrophages as measured by the trypan blue exclusion
test.
4. Discussion
TNF-α production has been studied within humans by
comparing groups of smokers, nonsmokers, smokers with
COPD and healthy smokers without COPD, using samples from
BAL fluid, induced sputum and serum. Kushner and coworkers
report that the concentration of TNF-α in the pulmonary
microenvironment is greater in healthy smokers compared to
healthy nonsmokers [21]. However, in a study using induced
sputum sample, a non-invasive method of studying airway
secretion, showed that the concentration of TNF-α is greater in
smokers with COPD compared to healthy smokers and
nonsmokers [22]. Takabatake and coworkers found increasedserum concentration of TNF-α in patients with COPD
compared to healthy nonsmoking subjects [23]. The acute
effect of smoke exposure on mice was studied by Churg and
coworkers. A single acute smoke exposure from four cigarettes
caused an increase in the gene expression of TNF-α from whole
lung extract 2 h after smoke treatment [24].
There have been several studies on the effect of cigarette
smoke on TNF-α production. Wang and coworkers showed that
nicotine, a component of cigarettes, induces the release of TNF-
α by cultured Ana-1 macrophages; furthermore, the TNF-α
released induces the expression of adhesion molecules such as
ICAM-1, VCAM-1 and E-selectin on endothelial cells which
lead to an increase in adherence of monocytes to the endothelial
cells [25]. In another study, alveolar macrophages from cigarette
smokers were shown to release greater amounts of TNF-α at
baseline and after treatment with LPS and IL-1β, compared to
alveolar macrophages from nonsmokers [26]. However, there
are other studies using blood monocytes, cultured alveolar
macrophages and BAL fluid which state that cigarette smoke
exposure reduces or has no effect on TNF-α production [27–
31]. Our results concur with the previous studies showing that
cigarette smoke does induce TNF-α release by macrophages,
since we could easily detect increased TNF-α production in
response to CSM exposure in both a time and dose-dependent
fashion. We further explored the mechanism by which cigarette
Fig. 4. Effect of AG1478 and LY294002 on TNF-α release. TNF-α release
without (red bar) or with (blue bar) pretreatment with [A] PI3-K inhibitor U0126
(6 μM), [B] and EGFR-specific inhibitor AG1478. Both inhibitors had no effect
on CSM-induced TNF-α release. Each bar represents the mean value±S.D. from
3 independent experiments.
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gating a number of signaling enzymes.
The MAP kinases (erk1/2, p38 and JNK) have been reported
to mediate production of proteases and cytokines in response to
a variety of stimuli. The effect of cigarette smoke or other
components of cigarettes have been investigated for their roles
in activation of MAPK-erk1/2 in fibroblasts, smooth muscle
cells, pulmonary epithelial cells and bronchoalveolar cells. In
normal human bronchial epithelial cells and small airway
epithelial cells, treatment with cigarette smoke extract increased
phosphorylation of erk1/2 [19, 32]. In addition, a study by
Zhang and coworkers shows that EGFR-specific inhibitor
AG1478 blocked cigarette smoke induced erk1/2 phosphory-
lation in nonmalignant human bronchiole epithelial cell line
[33]. In vascular smooth muscle cells and fibroblasts, treatment
with nicotine also induced the activation of erk1/2 [34].
However, in a different study, the erk1/2 was phosphorylated
by LPS in bronchoalveolar cells (BAC) from smokers and
nonsmokers, and the kinetics of activation were similar in both
groups [20].
In this study, we showed that cigarette smoke activates
human macrophages and induces the release of TNF-α, and this
release was dependent primarily on the activation of the erk1/2
signaling pathway. Activation of erk1/2 in turn induces the
activation of the downstream kinase p90RSK and may have
some effect on the activation of p70 S6 kinase. We could show
that inhibition of MEK1/2, the upstream activators of erk1/2,completely blocked CSM-induced erk1/2 phosphorylation, as
well as p90RSK phosphorylation. However, there was no effect
on phosphorylation of S6 ribosomal protein, and thus no effect
on p70S6 kinase activity. Macrophages exposed to CSM
showed a consistent decrease in the level of PKB phosphory-
lation, particularly at early times of exposure. Inhibition of the
PI 3-kinase enzymes with LY294002, which inhibits activation
of PKB, had no effect on the release of TNF-α in response to
CSM. Also EGFR-specific inhibitor AG1478 did not effect
CSM-induced TNF-α release by macrophages.
In conclusion, the current study demonstrates that macro-
phages exposed to cigarette smoke products are activated and
release TNF-α. Since this single event has been shown to play a
vital role in inflammatory responses, it represents a possible
mechanism whereby cigarette smoke may lead to pulmonary
conditions. Our studies also emphasize the importance of the
erk1/2 pathway, which is activated by exposure to CSM and
which is necessary for the CSM-induced release of TNF-α.
Further studies will be required to fully understand how
components of cigarette smoke activate signaling pathways and
to investigate other pathways that may also be playing a role in
macrophage activation. Furthermore, it will be important to test
these same pathways and the response to CSM in primary
human macrophages.
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